Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AUSTIN, TX AND DURHAM, NC, OCT. 02, 2025 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-RELATED DISEASES, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A PANEL DISCUSSION FOCUSED ON KEY TAKEAWAYS FROM THE UNITED EUROPEAN GASTROENTEROLOGY WEEK (UEGW) CONFERENCE 2025. THE SESSION WILL BE MODERATED BY COVERING ANALYSTS MARTIN FAN, PH.D.

SHATTUCK LABS ANNOUNCES PARTICIPATION IN UPCOMING WEDBUSH SECURITIES KEY OPINION LEADER (KOL) AND COMPANY PANEL

 AGGREGATE NET PROCEEDS FROM PRIVATE PLACEMENT EXPECTED TO FUND SL-325 THROUGH MULTIPLE PHASE 2 CLINICAL TRIALS, INCLUDING IN INFLAMMATORY BOWEL DISEASE (IBD) AND POTENTIALLY ANOTHER AUTOIMMUNE DISEASE

SHATTUCK LABS ANNOUNCES CLOSING OF UP TO $103 MILLION PRIVATE PLACEMENT AND APPOINTMENTS TO BOARD OF DIRECTORS

SL-325 IS A POTENTIALLY FIRST-IN-CLASS DR3 ANTAGONIST ANTIBODY BEING DEVELOPED FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND OTHER INFLAMMATORY AND IMMUNE-MEDIATED DISEASES 

SHATTUCK LABS ANNOUNCES IND FOR SL-325 IS IN EFFECT FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO EVALUATE SL-325 IN A PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS; CLEARANCE EXPECTED IN Q3 2025 

SHATTUCK LABS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

 AGGREGATE NET PROCEEDS EXPECTED TO FUND SL-325 THROUGH MULTIPLE PHASE 2 CLINICAL TRIALS, INCLUDING IN INFLAMMATORY BOWEL DISEASE (IBD) AND POTENTIALLY ANOTHER AUTOIMMUNE DISEASE 

SHATTUCK LABS ANNOUNCES OVERSUBSCRIBED PRIVATE PLACEMENT OF UP TO APPROXIMATELY $103 MILLION

AUSTIN, TX AND DURHAM, NC, JULY 02, 2025 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-RELATED DISEASES, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A DR3/TL1A FOCUSED PANEL DISCUSSION AND PARTICIPATE IN ONE-ON-ONE MEETINGS AT THE LEERINK PARTNERS THERAPEUTICS FORUM: I&I AND METABOLISM ON JULY 89, 2025 IN BOSTON, MA. CONFERENCE DETAILS FORMAT: PANEL DISCUSSION AND ONE-ON-ONE MEETINGS SESSION TITLE: TL1A: PIONEERING A NEW MOA IN IBD AND BEYOND MODERATORS: THOMAS J.

SHATTUCK LABS ANNOUNCES PARTICIPATION IN UPCOMING LEERINK PARTNERS THERAPEUTICS FORUM: I&I AND METABOLISM

 COMPANY ADVANCES SL-325 PROGRAM WITH AN IND FILING EXPECTED IN THE THIRD QUARTER OF 2025   CASH BALANCE OF APPROXIMATELY $60.9 MILLION AS OF MARCH 31, 2025, EXPECTED TO FUND OPERATIONS INTO 2027  AUSTIN, TX AND DURHAM, NC, MAY 01, 2025 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-MEDIATED DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDED RECENT BUSINESS HIGHLIGHTS. ALL IND-ENABLING ACTIVITIES AND REGULATORY INTERACTIONS REMAIN ON-TRACK TO INITIATE THE PHASE 1 CLINICAL TRIAL FOR SL-325 IN THE THIRD QUARTER OF THIS YEAR.

SHATTUCK LABS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

AUSTIN, TX AND DURHAM, NC, APRIL 02, 2025 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-RELATED DISEASES, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PRESENT AT AND PARTICIPATE IN ONE-ON-ONE MEETINGS AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE, TAKING PLACE APRIL 710, 2025.

SHATTUCK LABS ANNOUNCES PARTICIPATION IN UPCOMING 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

 PRESENTED PRECLINICAL NON-HUMAN PRIMATE (NHP) DATA AT THE 20TH CONGRESS OF EUROPEAN CROHN'S AND COLITIS ORGANIZATION IN INFLAMMATORY BOWEL DISEASES 2025 (ECCO) FOR SL-325, A POTENTIALLY FIRST-IN-CLASS BLOCKING ANTIBODY TO DR3, THE RECEPTOR FOR TL1A; DATA DEMONSTRATED FAVORABLE SAFETY PROFILE, FULL RECEPTOR OCCUPANCY, LACK OF DR3 AGONISM 

SHATTUCK LABS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

SL-325 IS A HIGH-AFFINITY DR3 BLOCKING ANTIBODY BEING DEVELOPED FOR THETREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD); NO EVIDENCE OF TOXICITY OR RESIDUAL AGONISM OBSERVED IN NON-HUMAN PRIMATE TOXICOLOGY STUDY  SL-325 RECEPTOR OCCUPANCY (RO) AND PHARMACOKINETIC (PK) PROFILE OBSERVED SUGGESTIVE OF EXTENDED DOSING INTERVALS; IND FILING EXPECTED IN THE THIRD QUARTER OF 2025  AUSTIN, TX & DURHAM, NC, FEB. 20, 2025 (GLOBE NEWSWIRE) -- SHATTUCK LABS, INC. (SHATTUCK) (NASDAQ: STTK), A BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF NOVEL THERAPEUTICS TARGETING TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTORS FOR THE TREATMENT OF PATIENTS WITH INFLAMMATORY AND IMMUNE-RELATED DISEASES, TODAY ANNOUNCED POSITIVE PRECLINICAL DATA FROM AN IND-ENABLING GLP TOXICOLOGY STUDY OF SL-325 IN NON-HUMAN PRIMATES (NHP). THESE DATA WERE FEATURED IN A DIGITAL ORAL PRESENTATION ON FEBRUARY 20, 2025,DURING THE 20TH CONGRESS OF ECCO IN INFLAMMATORY BOWEL DISEASES 2025 IN BERLIN, GERMANY.

SHATTUCK LABS ANNOUNCES POSITIVE DATA FROM THE PRECLINICAL GLP TOXICOLOGY STUDY OF SL-325 AT THE 20TH CONGRESS OF EUROPEAN CROHN'S AND COLITIS ORGANIZATION (ECCO) IN INFLAMMATORY BOWEL DISEASES 2025

Shattuck Labs, Inc.

STTK

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Shattuck Labs, Inc.

STTK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

STTK